FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to new compounds of general formula (I)
where R1 represents a hydrogen atom or a C1-C3 alkyl group, X represents NR2R3, OR4, a piperazinyl group which may contain one or more groups selected from an alkyl group and an oxo group, or a morpholino group, as well as pharmaceutical compositions based on them and use for the treatment of tumors with EGFR mutation.
EFFECT: new compounds with inhibitory effect on mutant EGFR that may be useful for treating tumors with EGFR mutation.
14 cl, 13 tbl, 74 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRIMIDINE COMPOUND OR ITS SALT | 2020 |
|
RU2787992C1 |
| C26-LINKED ANALOGUES OF RAPAMYCIN AS MTOR INHIBITORS | 2019 |
|
RU2826559C2 |
| C40-, C28- AND C-32-LINKED RAPAMYCIN ANALOGUES AS MTOR INHIBITORS | 2019 |
|
RU2805211C2 |
| 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 (IKZF2) OF THE IKAROS FAMILY | 2019 |
|
RU2797559C2 |
| 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USE THEREOF IN TREATING DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 OF IKAROS (IKZF2) FAMILY | 2019 |
|
RU2815714C2 |
| CALICHEAMICIN DERIVATIVES AND THEIR ANTIBODY-DRUG CONJUGATES | 2018 |
|
RU2732568C1 |
| AZALACTAM COMPOUNDS AS INHIBITORS OF HPK1 | 2021 |
|
RU2819642C1 |
| ANTIBODY-STING AGONIST CONJUGATES AND USE THEREOF IN IMMUNOTHERAPY | 2020 |
|
RU2826228C2 |
| COMPOSITIONS FOR TREATING CANCER USING ANTAGONISTS WHICH BIND TO THE PD-1 SIGNALING PATHWAY COMPONENT AND MEK INHIBITORS | 2015 |
|
RU2733735C2 |
| METASTIN DERIVATIVES AND USE THEREOF | 2007 |
|
RU2454425C2 |
